A Clinical Approach to Identifying Toxic Exposure Risks

Learn about the clinical approach to toxic exposure and how it can inform effective treatment and prevention strategies.

Abstract

In this comprehensive educational post, I, Dr. Alex Jimenez, will guide you through a clinically grounded journey to recognize and manage a wide range of common and complex toxicological emergencies. Drawing on modern, evidence-based research and insights from leading experts, we will explore the intricate pathophysiology and treatment of various poisonings from an integrative perspective. This guide is designed to be easy to understand, taking you from foundational principles to advanced therapeutic strategies. We will cover the management of major toxidromes (anticholinergic, cholinergic, sympathomimetic), specific ingestions like acetaminophen, salicylates, and toxic alcohols (ethylene glycol, methanol), and inhalational injuries from cyanide and carbon monoxide. We will also delve into cardiotoxic overdoses from beta-blockers and calcium channel blockers, detailing advanced therapies like high-dose insulin euglycemia therapy (HIET), glucagon, and intralipid rescue. Further topics include the nuanced use of naloxone for clonidine and xylazine toxicity, serotonin syndrome, sulfonylurea-induced hypoglycemia with octreotide, anticoagulant reversal, and the careful use of flumazenil.

A central theme of this post is the unique multidisciplinary approach we employ at Injury Medical Clinic, PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. I will detail how my work in chiropractic, advanced practice nursing, and functional medicine integrates with the invaluable medical oversight of our Medical Director, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas, a board-certified internist with over 40 years of experience, provides the essential medical direction that anchors our collaborative practice. Together, we offer a spectrum of services—including chiropractic adjustments, functional medicine diagnostics, medical management, personal injury care, and comprehensive rehabilitation—to support our patients’ return to optimal function. This integrated framework is particularly beneficial for patients recovering from the systemic and neurological consequences of toxic exposures, providing a holistic path to wellness that addresses both immediate needs and long-term recovery.

Our Integrative Team: A Collaborative Approach to Health

At Injury Medical Clinic, PA, also known as Mission Plaza Injury Medical Clinic, we believe in a patient-centered, multidisciplinary framework. Our strength lies in the synergy between different fields of healthcare, all united under one roof to provide comprehensive and cohesive treatment plans. I have always believed that the most practical educational content is grounded in lived clinical experience, clear physiology, and a system of care that puts patient safety first.

I am Dr. Alex Jimenez, and my background spans chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP, ATN, CCST). This diverse training allows me to view patient health through multiple lenses—structural, neurological, metabolic, and systemic.

Working alongside me as our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and brings over four decades of invaluable experience to our practice. Her NPI is #1164426749, and her Texas MD License is #J2933. This collaborative relationship is foundational to our practice, particularly in an integrative or injury care setting. Dr. Cardenas provides essential medical direction and oversight, ensuring that our treatment protocols meet the highest standards of medical safety and efficacy. Her leadership ensures the safe implementation of acute rescue therapies, evidence-aligned diagnostic testing, coordination of specialist referrals, and the integration of functional and chiropractic care into medically appropriate recovery plans.

Together, our team seamlessly integrates a spectrum of services:

• Medical Oversight (Dr. Cardenas): Provides diagnostic clarity, manages complex medical conditions, prescribes necessary medications, orders and interprets advanced imaging and lab tests, and oversees the medical aspects of patient care, ensuring all treatments are appropriate and safe.
• Chiropractic Care (Dr. Jimenez): Focuses on restoring spinal and musculoskeletal integrity. After a toxic exposure, patients may experience muscle weakness, spasms, or neurological deficits that lead to biomechanical imbalances. Chiropractic adjustments and soft tissue therapies can alleviate these secondary issues, improve nervous system function, and support thebody’ss recovery process.
• Functional Medicine: We delve deep to identify the root causes of dysfunction. Toxicology is a prime example where we look beyond the acute event to assess how the toxin has impacted gut health, detoxification pathways, mitochondrial function, and nutritional status, creating personalized plans to restore balance.
• Rehabilitation and Personal Injury Care: Our team develops tailored rehabilitation programs to help patients regain strength, mobility, and function following an injury or a severe medical event like a poisoning. We deploy multimodal rehabilitation—active care, corrective exercise, and biomechanical retraining—always under medical safety parameters defined by Dr. Cardenas.

This model ensures that a patient presenting with a complex issue, such as the after-effects of a toxic ingestion, receives holistic care. While the immediate medical crisis is managed, we simultaneously address the structural, neurological, and metabolic fallout, paving the way for a more complete and lasting recovery. The clinical scenarios below are presented from my vantage point in practice and informed by leading toxicology and emergency medicine researchers. I emphasize how our team coordinates acute stabilization with follow-through, and how integrative chiropractic care is safely incorporated when appropriate to support neuromusculoskeletal function, autonomic regulation, and rehabilitation.

Decoding Toxic Ingestions: Foundational Principles

Before we delve into specific toxins, it is essential to establish a universal framework for managing any patient with a suspected toxic exposure. The initial moments of care are often the most critical, and a systematic approach can be lifesaving.

The Universal Approach: ABCs and Beyond

No matter the toxin, the foundational principles of emergency medicine always apply. Our primary assessment is paramount unless there is an immediate safety threat (like an ongoing chemical exposure).

• Airway, Breathing, Circulation (ABCs): This is our unwavering priority. Is the airway open and protected? Is the patient breathing effectively? Do they have adequate circulation and perfusion? Any compromise in the ABCs must be addressed immediately.
• Check a Glucose Level: In any patient with an altered mental status, a point-of-care blood glucose check is mandatory. Many toxins can interfere with glucose metabolism. Some may inhibit the release of insulin from the pancreas. In contrast, others may prevent glucose from entering the cells, leading to profound hypoglycemia or hyperglycemia that can mimic or worsen the toxic effects.
• The Power of Benzodiazepines: If I had to choose a single “go-to” medication for the initial management of many toxic emergencies, it would be a benzodiazepine, such as midazolam or lorazepam. These drugs are incredibly effective for treating a wide range of “hyper” states caused by toxins:

• • Hypertension (high blood pressure)
  • Tachycardia (rapid heart rate)
  • Hyperthermia (high body temperature)
  • Agitation and hyperactivity
  • Acute psychosis
  • Seizures

• By enhancing the effect of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) in the central nervous system, benzodiazepines provide a calming effect that can stabilize the patient, prevent complications like rhabdomyolysis, and allow for further diagnostic workup.

The Primacy of Decontamination

One of the first considerations, even before the patient enters the clinical setting, is decontamination, or “decon”. This is especially true for dermal or inhalation exposures. If a patient arrives at our practice covered in an unknown substance, our priority is to mitigate further absorption and protect our staff and other patients.

• Dermal Exposure: Many chemicals are readily absorbed through the skin. The vast majority of these substances can be safely and effectively removed with copious amounts of water. It is a simple yet powerful intervention. While there are rare exceptions (e.g., certain dry powders or metals that react with water), water irrigation is the standard of care.
• Inhalation Exposure: If a toxic substance has been inhaled, the first step is to move the patient to fresh air, away from the source of exposure, while administering supplemental oxygen as needed.

Rethinking Gastrointestinal (GI) Decontamination

For decades, the standard approach to toxic ingestions involved aggressive GI decontamination methods. However, modern, evidence-based research has led to a significant shift in these practices.

• Induction of Emesis (Vomiting): The practice of inducing vomiting, for instance, with syrup of ipecac, is no longer recommended. Extensive reviews of patient outcomes have shown that this method offers little benefit in removing the toxin and carries a substantial risk of complications, most notably aspiration (inhaling vomit into the lungs), which can lead to severe pneumonia and respiratory failure. Poison control centers have ceased recommending this practice for home or clinical use.
• Gastric Lavage (Stomach Pumping): Similarly, gastric lavage is now rarely performed. For it to be effective, it must be initiated very soon after ingestion, typically within the first hour. Most patients do not present to a clinical setting within this narrow window. Furthermore, the procedure itself is invasive and can cause physical trauma or trigger aspiration. Its utility in most toxicological scenarios is extremely low.
• Whole Bowel Irrigation (WBI): This method still has a place in modern toxicology, but its use is specific. WBI involves administering large volumes of a polyethylene glycol (PEG) electrolyte solution to flush the entire gastrointestinal tract. It is reserved for situations where a patient has ingested a substance that is:

• • Highly toxic.
  • Not well-adsorbed by activated charcoal (e.g., iron, lithium, heavy metals).
  • Sustained-release or long-acting.
  • Potentially corrosive to the GI tract.

• WBI is also the treatment of choice for “body packers” who have ingested packets of illicit drugs, as it facilitates their rapid and safe evacuation before the packets can rupture.

The Role of Activated Charcoal

Activated charcoal remains a valuable tool in our arsenal, provided it is used correctly. It works by a process called adsorption, where the toxin molecules bind to the vast surface area of the charcoal particles, preventing their absorption from the GI tract into the bloodstream.

• Timing is Critical: For activated charcoal to be effective, it must be administered within a reasonable timeframe, generally within the first one to four hours of ingestion for most substances. The sooner, the better.
• Patient Safety First: The single most important consideration before administering activated charcoal is the patient’s airway protection and mental status. If a patient is lethargic, obtunded, or unable to protect their own airway, giving charcoal orally is contraindicated due to the high risk of vomiting and aspiration. In such cases, the airway must first be secured with an endotracheal tube before charcoal is administered via a nasogastric or orogastric tube.
• Limitations of Charcoal: It is crucial to remember that activated charcoal does not bind to everything. It is ineffective against:

• • Pesticides
  • Hydrocarbons (like gasoline)
  • Alcohols and glycols (like ethylene glycol)
  • Iron
  • Lithium
  • Solvents and strong acids/alkalis

(The mnemonic “PHAILS” can be helpful here).

• Use with a Cathartic: Activated charcoal is often premixed with a cathartic agent like sorbitol. A cathartic is a laxative that speeds up the transit of the charcoal-toxin complex through the intestines, facilitating its elimination from the body. If the preparation does not contain a cathartic, one should be administered alongside the first dose.

Understanding Toxidromes: Clinical Clues to the Culprit

A toxidrome is a constellation of signs and symptoms that are characteristic of a specific class of poisons. Recognizing these patterns is a cornerstone of clinical toxicology, as it allows us to form a differential diagnosis and initiate empiric treatment even before laboratory confirmation is available. Toxidromes are typically identified by assessing vital signs, pupil size, skin condition, and mental status.

The Anticholinergic Toxidrome: Hot, Dry, and Agitated

Let’s begin with a clinical scenario. We are evaluating a two-year-old child brought in by paramedics for an unknown ingestion and seizure activity. Their vital signs are: heart rate 180 bpm, blood pressure 130/80 mmHg, respiratory rate 30, and a temperature of 103°F (39.4°C). On examination, their pupils are markedly dilated (mydriasis).

Two vital signs immediately demand our attention: the profound tachycardia and the significant hyperthermia. A 12-lead electrocardiogram (ECG) is performed; despite the rapid rate, it reveals a dangerously wide QRS complex, measuring well over 100 milliseconds. To complete the picture, we note that the child’s skin is flushed, hot, and completely dry.

This collection of findings—tachycardia, hyperthermia, mydriasis, altered mental status (seizures), dry skin, and a wide QRS—is the classic presentation of the anticholinergic toxidrome.

A helpful mnemonic to remember these features is:

• Blind as a bat (Mydriasis causing blurry vision)
• Red as a beet (Flushed skin from vasodilation)
• Hot as a hare (Hyperthermia due to inhibited sweating)
• Dry as a bone (Dry skin and mucous membranes)
• Mad as a hatter (Agitation, delirium, psychosis, seizures)
• Full as a flask (Urinary retention)

Pathophysiology Explained:

Anticholinergic agents work by blocking the action of the neurotransmitter acetylcholine at muscarinic receptors. Acetylcholine is a key player in the “rest and digest” parasympathetic nervous system. By blocking its effects, the “fight or flight” sympathetic nervous system becomes unopposed, leading to the characteristic signs and symptoms.

• Heart: Blockade of muscarinic receptors on the heart’s sinoatrial (SA) node removes the parasympathetic “brake,” leading to tachycardia.
• Sweat Glands: Sweat glands are controlled by the sympathetic nervous system, but uniquely, they use muscarinic receptors. Blocking these receptors inhibits sweating, which is the body’s primary mechanism for cooling. This leads to dangerous hyperthermia.
• Brain: Muscarinic receptors in the central nervous system are crucial for cognition and arousal. Blocking them causes confusion, delirium, and seizures.
• Sodium Channel Blockade: The wide QRS on the ECG is a particularly ominous sign, indicating a sodium channel blockade. Certain anticholinergic drugs, most notably Tricyclic Antidepressants (TCAs), also block fast sodium channels in the cardiac muscle cells (myocytes). This slows down the electrical conduction through the ventricles, widening the QRS complex and predisposing the patient to life-threatening arrhythmias like ventricular tachycardia and fibrillation.

Common Causes:

• Antihistamines: Many over-the-counter allergy and sleep medications (e.g., diphenhydramine).
• Antipsychotics and Antidepressants: Especially older agents like TCAs (e.g., amitriptyline) and some atypical antipsychotics.
• Antispasmodics: Medications used for irritable bowel syndrome (e.g., dicyclomine).
• Atropine: A classic anticholinergic drug.
• Certain Plants: Jimsonweed (Datura stramonium) and deadly nightshade (Atropa belladonna).

Management Strategy:

1. ABCs and Supportive Care: As always, our priority is to manage the airway, breathing, and circulation. Seizures are treated aggressively with benzodiazepines.
2. Cooling Measures: Active cooling is essential to manage the hyperthermia. This can include fans, misting, and cooling blankets.
3. Sodium Bicarbonate for Cardiotoxicity: The presence of a wide QRS complex (>100 ms) is an absolute indication for intravenous sodium bicarbonate. This is the cornerstone of treatment for TCA-induced cardiotoxicity. It works through two mechanisms:

• • pH Alteration: The bicarbonate infusion makes the blood more alkaline (increases the pH). This change in pH alters the TCA molecule, causing it to bind more readily to plasma proteins, thereby decreasing the amount of “free” drug available to poison the sodium channels.
  • Sodium Gradient: The infusion provides a large sodium load, which increases the electrochemical gradient across the cardiac cell membrane, helping to overcome the sodium channel blockade.

The goal is to narrow the QRS complex and stabilize the cardiac membrane. This is often initiated with a bolus followed by a continuous infusion.

• Vasopressors: If the patient remains hypotensive despite fluid resuscitation, a vasopressor like norepinephrine is the agent of choice.
• Activated Charcoal: If the patient presents within a couple of hours of ingestion and has a secure airway, activated charcoal can be beneficial.
• Hemodialysis: Unfortunately, most anticholinergic drugs, particularly TCAs, are highly protein-bound and have a large volume of distribution, meaning they are not effectively removed by hemodialysis. However, dialysis may be used to manage severe acidosis or renal failure if it develops.

The Cholinergic Toxidrome: Wet and Weak

Now, let’s consider a different scenario. A patient presents after ingesting a pesticide. What signs and symptoms should we anticipate? The answer is a cholinergic crisis, which is essentially the polar opposite of the anticholinergic toxidrome.

An excess of acetylcholine causes this toxidrome. The classic culprits are organophosphates and carbamates, which are found in many insecticides, pesticides, and, terrifyingly, in chemical warfare nerve agents (e.g., Sarin, Soman, VX).

Pathophysiology Explained:

These substances work by inhibiting the enzyme acetylcholinesterase. The normal function of this enzyme is to break down acetylcholine in the synaptic cleft, thereby terminating its signal. When acetylcholinesterase is inhibited, acetylcholine accumulates and persistently stimulates both muscarinic and nicotinic receptors throughout the body, leading to massive overstimulation.

Muscarinic Effects (“Wet” ):

The overstimulation of muscarinic receptors leads to profound parasympathetic effects. A common mnemonic for these is SLUDGE-BBB or DUMBBELS:

• Salivation
• Lacrimation (tearing)
• Urination
• Defecation
• GI distress (cramping, vomiting)
• Emesis (vomiting)
• Bronchorrhea (excessive fluid production in the airways)
• Bronchospasm (constriction of the airways)
• Bradycardia (slow heart rate)

The primary clinical danger from the muscarinic effects is airway compromise. The combination of massive fluid production (bronchorrhea) and airway constriction (bronchospasm) can rapidly lead to respiratory failure and asphyxiation.

Nicotinic Effects (“Weak” ):

Overstimulation of nicotinic receptors, which are found at the neuromuscular junction (where nerves meet muscles) and in autonomic ganglia, causes an initial phase of twitching and fasciculations, followed by profound muscle weakness and paralysis.

A mnemonic for nicotinic effects corresponds to the days of the week:

• Mydriasis (or Miosis – pupil size can be variable)
• Tachycardia
• Weakness
• Hypertension
• Fasciculations (muscle twitching)
• Seizures
• Sweating

The most life-threatening nicotinic effect is the paralysis of the diaphragm, the primary muscle of respiration. This, combined with the muscarinic-induced airway flooding, creates a lethal scenario where the patient cannot breathe and effectively drowns in their own secretions.

Management Strategy:

1. DECONTAMINATION IS CRITICAL: Organophosphates can be readily absorbed through the skin. Healthcare providers must wear appropriate personal protective equipment (PPE), and the patient must be thoroughly decontaminated with soap and water before entering the main treatment area to prevent cross-contamination.
2. Airway Management: The top priority is securing the airway. This often requires aggressive suctioning and early intubation. The head of the bed should be elevated.
3. Atropine (The Drying Agent): The first-line pharmacological treatment is atropine. Atropine is a competitive antagonist at muscarinic receptors. It works by blocking the effects of excess acetylcholine at these sites, primarily to dry secretions (bronchorrhea, salivation) and reverse bronchospasm and bradycardia.

• • Dosing: Large doses are required. We may start with 2-5 mg intravenously and repeat every few minutes. There is no maximum dose of atropine in this setting. The clinical endpoint is the drying of pulmonary secretions, not a specific heart rate.

• Pralidoxime (2-PAM) (The Antidote): While atropine is a symptomatic treatment, pralidoxime (2-PAM) is the true antidote. It works by reactivating the acetylcholinesterase enzyme that the organophosphate has inhibited. This allows the body to break down the excess acetylcholine, addressing both the muscarinic and nicotinic effects (especially muscle weakness).

• • Timing is Key: 2-PAM must be administered as early as possible. Over time, the bond between the organophosphate and the enzyme undergoes a process called “aging,” where it becomes permanent and irreversible. Once aging has occurred, 2-PAM is no longer effective.

• Benzodiazepines: Seizures are common in severe organophosphate poisoning and should be treated with benzodiazepines.

The Sympathomimetic Toxidrome: Hot, Wet, and Agitated

Let’s imagine an adult male presents with chest pain. His friends report he may have overdosed on cocaine. We would expect to find signs of profound central nervous system and cardiovascular stimulation: euphoria, restlessness, agitation, and potentially paranoia or psychosis. This is the sympathomimetic toxidrome.

This toxidrome results from excessive stimulation of the sympathetic nervous system (“fight or flight”). It is caused by drugs like cocaine, amphetamines, methamphetamine, and synthetic cathinones (“bath salts”).

Pathophysiology Explained:

These drugs work by increasing catecholamine levels—norepinephrine, dopamine, and serotonin—in the synapse. They do this by blocking their reuptake or promoting their release. The resulting surge in these neurotransmitters leads to widespread sympathetic activation.

Clinical Presentation:

The features of the sympathomimetic toxidrome can be remembered with the mnemonic MASS:

• Mydriasis (dilated pupils)
• Agitation, Arrhythmias, Angina (chest pain)
• Seizures, Sweating (diaphoresis)
• Severe hypertension, Severe tachycardia

Key manifestations include:

• Cardiovascular: Tachycardia, hypertension, coronary vasospasm (which can cause a heart attack even in young people with healthy arteries), and arrhythmias.
• Neurological: Agitation, euphoria, paranoia, psychosis, tremors, and seizures.
• Metabolic: Hyperthermia is a hallmark and a major cause of mortality. It results from increased motor activity (agitation), vasoconstriction, and a direct effect on the hypothalamus. Rhabdomyolysis (muscle breakdown) is a common and dangerous complication of hyperthermia and intense muscle activity.

Differentiating from Anticholinergic Toxidrome:

Both sympathomimetic and anticholinergic toxidromes present with tachycardia, hypertension, mydriasis, and hyperthermia. The key differentiating feature is the skin.

• Anticholinergic: Hot and DRY (sweating is inhibited).
• Sympathomimetic: Hot and WET (sweating/diaphoresis is present and often profuse).

Management Strategy:

1. Benzodiazepines, Benzodiazepines, Benzodiazepines: These are the first-line and most important treatment. They control agitation, treat seizures, and, by sedating the patient, help lower heart rate, blood pressure, and core body temperature.
2. Hydration and Cooling: Aggressive intravenous hydration is crucial to protect the kidneys from myoglobin released during rhabdomyolysis. Active cooling measures are vital to combat the life-threatening hyperthermia.
3. Managing Hypertension and Chest Pain: If benzodiazepines are not sufficient to control severe hypertension or cocaine-associated chest pain, the next step is typically a vasodilator like nitroglycerin or phentolamine.
4. THE DANGER OF BETA-BLOCKERS: A critical teaching point is the contraindication of pure beta-blockers (like metoprolol) in this setting. Sympathomimetic drugs stimulate both alpha- and beta-adrenergic receptors. Alpha-receptors cause vasoconstriction, while beta-receptors cause vasodilation (in skeletal muscle) and increase heart rate. If you block the beta-receptors alone, you leave the alpha-receptors unopposed. This leads to “unopposed alpha stimulation,” resulting in severe, paradoxical worsening of hypertension and coronary vasospasm.

• • If a beta-blocker is deemed necessary, an agent with both alpha- and beta-blocking properties, such as labetalol, is the preferred choice.

• Sodium Bicarbonate for Cocaine: Cocaine, similar to TCAs, can also act as a sodium channel blocker, causing a wide QRS on the ECG. In these cases, intravenous sodium bicarbonate is indicated, just as it is for TCA toxicity.
• GI Decontamination: Activated charcoal can be used for acute ingestions. For body packers, whole bowel irrigation is the treatment of choice.

A Deeper Look at Specific Toxicities and Advanced Management

Beyond the major toxidromes, let’s explore the management of some of the most common and challenging individual poisonings.

Acetaminophen (Paracetamol) Toxicity

Acetaminophen overdose is one of the most common poisonings worldwide and a leading cause of acute liver failure. The danger of acetaminophen lies in its toxic metabolite. The toxicodynamics hinge not on acetaminophen itself, but on the hepatic generation of NAPQI (N-acetyl-p-benzoquinone imine), a reactive metabolite produced via CYP2E1. When glutathione stores are depleted, NAPQI binds hepatocellular proteins, triggering oxidative stress, mitochondrial dysfunction, and centrilobular hepatic necrosis (Prescott, 1983; Lee, 2017).

Pathophysiology Explained:

Under normal conditions, most acetaminophen is metabolized in the liver through safe pathways (glucuronidation and sulfation). A small fraction is metabolized by the cytochrome P450 system (specifically CYP2E1) into a highly reactive and toxic metabolite called N-acetyl-p-benzoquinone imine (NAPQI). Normally, this small amount of NAPQI is immediately detoxified by binding to glutathione, a powerful antioxidant in the liver, and is then safely excreted.

In an overdose situation, with a single ingestion >150 mg/kg, the primary glucuronidation and sulfation pathways become saturated. This shunts a much larger proportion of the acetaminophen down the P450 pathway, leading to the production of massive amounts of NAPQI. The liver’s stores of glutathione are rapidly depleted. Once glutathione is gone, the free NAPQI begins to bind to and destroy liver cells (hepatocytes), leading to centrilobular necrosis and, ultimately, acute liver failure.

Clinical Staging:

Acetaminophen toxicity typically progresses through four clinical stages:

• Stage 1 (0-24 hours): Patients may be asymptomatic or have mild, nonspecific symptoms like nausea and vomiting. This is the “silent” but critical period for intervention. Often overlooked due to benign appearance.
• Stage 2 (24-72 hours): Liver injury begins. Patients may develop right upper quadrant pain, and liver enzymes (AST, ALT) begin to rise.
• Stage 3 (72-96 hours): This is the stage of peak liver injury, or fulminant hepatic failure. Patients become jaundiced, coagulopathic (high INR), hypoglycemic, and develop encephalopathy. This stage carries a high mortality rate.
• Stage 4 (4 days to 2 weeks): Patients who survive Stage 3 begin the recovery phase, with gradual resolution of liver injury.

Management Strategy:

1. The Four-Hour Level: The cornerstone of diagnosis and risk stratification is the serum acetaminophen level. For an acute ingestion, the first level should ideally be drawn at least four hours post-ingestion. This is because it takes approximately four hours for acetaminophen to be fully absorbed from the GI tract. A level drawn before four hours may not accurately reflect the peak concentration and can be misleading.
2. The Rumack-Matthew Nomogram: The four-hour (or later) acetaminophen level is plotted on the Rumack-Matthew nomogram. This graph plots the serum acetaminophen concentration against the time since ingestion. If the patient’s level falls above the treatment line on the nomogram, they are considered to be at risk for hepatotoxicity, and treatment with the antidote is indicated.
3. The Antidote: N-Acetylcysteine (NAC): The antidote for acetaminophen poisoning is N-acetylcysteine (NAC). It is nearly 100% effective at preventing liver injury if started within 8 hours of ingestion but remains beneficial even after 24 hours (Smilkstein et al., 1988; Heard, 2008).

• • Mechanism of Action: NAC works in several ways:

• • • It acts as a precursor for the synthesis of new glutathione, replenishing the liver’s depleted stores.
    • It can act as a direct substitute for glutathione, binding to and detoxifying NAPQI.
    • It has antioxidant and anti-inflammatory properties that help protect the liver.

• • Administration: NAC can be given intravenously or orally. The IV protocol is now more commonly used in the US, typically as a 21-hour infusion, due to better tolerance.

Airway-First Priorities in Toxicology: The Critical Caveat of Compensatory Hyperventilation

In every acute patient scenario, I start with the ABCs. However, certain toxicology cases carry a pivotal caveat. When patients present with profoundly altered mental status and compensatory hyperventilation—as is common in salicylate poisoning and diabetic ketoacidosis (DKA)—their increased respiratory rate is an active physiologic defense against mounting metabolic acidosis. This hyperventilation reduces arterial CO2 (PaCO2) via respiratory alkalosis, buffering the acidic burden. If these patients require intubation, I must match their pre-intubation ventilation or risk precipitous decompensation.

Physiological Underpinning:

• In metabolic acidosis, bicarbonate buffering is overwhelmed. The respiratory system compensates by increasing minute ventilation to blow off CO2 (a volatile acid), elevating pH.
• Sudden reduction in ventilation increases PaCO2, lowers pH, and can trigger arrhythmias, hypotension, and death.
• In salicylate toxicity, there is a mixed acid-base disturbance: primary respiratory alkalosis (from medullary respiratory center stimulation) with concomitant metabolic acidosis (lactate production, ketoacids, salicylate-induced mitochondrial uncoupling). This makes careful ventilation matching critical (Salhanick & Shannon, 2007; Lavonas et al., 2015).

If intubation is necessary, it must be done with extreme caution, ensuring that the ventilator is set to a very high respiratory rate to match or exceed the patient’s pre-intubation minute ventilation to avoid a catastrophic drop in blood pH.

Salicylate (Aspirin) Toxicity: A Complex Metabolic Emergency

An elderly patient presents with arthritis pain and tinnitus (ringing in the ears). They have been self-medicating with an over-the-counter pain reliever. This presentation should immediately raise suspicion for salicylate (aspirin) toxicity. Tinnitus is a classic early sign of mild to moderate toxicity.

Pathophysiology Explained:

Salicylates cause a complex and dangerous mixed acid-base disturbance and disrupt cellular metabolism.

1. Respiratory Alkalosis: Salicylates directly stimulate the respiratory center in the brainstem, causing hyperventilation (tachypnea). This rapid breathing blows off excess carbon dioxide (CO2), leading to a primary respiratory alkalosis.
2. Anion Gap Metabolic Acidosis: This is the more dangerous component. Salicylates uncouple oxidative phosphorylation in the mitochondria. This is a critical concept. Salicylates disrupt the proton gradient used to produce ATP, causing energy production to become wildly inefficient. The body attempts to compensate by ramping up anaerobic metabolism, leading to the accumulation of organic acids like lactate and ketoacids. This results in a severe high anion gap metabolic acidosis.
3. Neuroglycopenia: Although blood glucose may be normal or even high, the uncoupling of oxidative phosphorylation prevents glucose from being effectively used by the brain, leading to neuroglycopenia (low glucose in the brain), which manifests as confusion, agitation, delirium, and coma.

The hallmark of severe salicylate poisoning is the co-existence of a respiratory alkalosis and a metabolic acidosis.

Management Strategy:

1. Supportive Care and GI Decontamination: Airway management is critical, with the hyperventilation caveat described above. Activated charcoal can be given.
2. Systemic Alkalinization (Urine and Serum): The cornerstone of treatment is intravenous sodium bicarbonate. The goal is to alkalinize both the serum and the urine.

• • Serum Alkalinization: Making the blood more alkaline (targeting a pH of 7.45-7.55) shifts the salicylate into its ionized form, trapping it in the bloodstream and pulling it out of tissues like the brain.
  • Urine Alkalinization: Making the urine more alkaline (targeting a urine pH > 7.5) dramatically increases the excretion of salicylates by the kidneys, a process called “ion trapping.” Potassium must be repleted, as hypokalemia impairs the kidney’s ability to alkalinize urine (Temple, 2002).

• Glucose Supplementation: Dextrose-containing IV fluids should be used to prevent neuroglycopenia.
• Hemodialysis: Hemodialysis is a definitive and lifesaving treatment for severe salicylate poisoning. It is indicated for patients with very high salicylate levels, severe acidosis, altered mental status, renal failure, or pulmonary edema (Levine, 2006; Juurlink et al., 2015). Dialysis rapidly removes the salicylate from the body and corrects the acid-base disturbances.

Serotonin Syndrome: Diagnosis, Differentiation from NMS, and Benzodiazepine-First Management

Serotonin syndrome arises due to excessive serotonergic activity, commonly from overdose of SSRIs, polypharmacy (MAO inhibitors, SNRIs, TCAs, tramadol, linezolid), or combination with St. John’s Wort. The syndrome presents with a triad of neuromuscular hyperactivity, autonomic instability, and altered mental status (Boyer & Shannon, 2005).

Clinical Features:

• Neuromuscular: Hyperreflexia, clonus (inducible or spontaneous), myoclonus, tremor.
• Autonomic: Hyperthermia, hypertension, tachycardia, diaphoresis, mydriasis.
• Mental status: Agitation, confusion, anxiety.

Differentiation from Neuroleptic Malignant Syndrome (NMS):

• Serotonin syndrome: Hyperreflexia and clonus are characteristic; onset can be rapid (hours).
• NMS: Lead-pipe rigidity, bradykinesia, hyporeflexia; onset typically slower (days).

Management:

• Benzodiazepines are first-line to control agitation and decrease neuromuscular excitation.
• Cyproheptadine, a serotonin antagonist, is used for moderate to severe cases.
• Discontinue all serotonergic agents and use external cooling and sedation for hyperthermia.

Botulism: Descending Paralysis

A family presents with complaints of symmetrical muscle weakness that began in their upper body and has now descended to their legs. They also complain of drooling (sialorrhea) and difficulty swallowing (dysphagia). This classic presentation points to botulism.

Pathophysiology Explained:

Botulism is caused by a potent neurotoxin produced by the bacterium Clostridium botulinum. It works at the neuromuscular junction by irreversibly blocking the release of acetylcholine from the presynaptic nerve terminal, leading to flaccid paralysis. The classic pattern of botulism is a symmetrical, descending paralysis, starting with the cranial nerves and progressing downwards to the muscles of respiration. This is in stark contrast to Guillain-Barré syndrome (GBS), which classically causes an ascending paralysis.

Management Strategy:

1. Supportive Care: The mainstay of treatment is meticulous supportive care, with a primary focus on monitoring for and managing respiratory failure. Many patients will require mechanical ventilation.
2. Antitoxin: The definitive treatment is the administration of botulism antitoxin. The antitoxin binds to and neutralizes any circulating toxin, preventing it from binding to more nerve terminals. It cannot reverse existing paralysis but halts the progression of the disease. Therefore, it must be administered as early as possible upon clinical suspicion.

Clonidine Toxicity: Recognition, Physiology, and Naloxone Strategy

In a pediatric scenario with altered mental status and respiratory depression, I always consider central alpha-2 agonists like clonidine. Clonidine reduces sympathetic outflow from the brainstem, producing sedation, bradycardia, hypotension, and respiratory depression, mimicking opioid toxicity (Olson, 2012).

Naloxone in Clonidine Toxicity: Mechanistic Rationale

Though naloxone is an opioid antagonist, evidence suggests that high-dose naloxone can partially reverse clonidine-induced respiratory depression, likely via disinhibition of arousal pathways or overlapping receptor dynamics (Kim & Nelson, 2015). In practice, I use naloxone because it is rapid-acting and can temporarily reverse respiratory depression. However, its short duration requires close monitoring for re-sedation. For suspected clonidine ingestion, I often employ higher naloxone dosing strategies, targeting complete reversal of respiratory compromise.

Xylazine (Tranq): Veterinary Alpha-2 Agonist and Tissue Injury

Xylazine, often adulterating street fentanyl, produces profound CNS depression, bradycardia, and hypotension. The alpha-2 agonism explains the tranquilization-like state, but the tissue destruction at injection sites is uniquely alarming, with necrosis and non-healing lesions (Ruiz-Colón et al., 2014; Kariisa et al., 2023). Naloxone may partially reverse respiratory depression when opioids are co-present, but xylazine itself is not an opioid. Management requires airway support, hemodynamics, and aggressive wound care.

Cardiotoxic Overdoses: Beta-Blockers and Calcium Channel Blockers

An adult presents with altered mental status, hypotension, and bradycardia. A fingerstick glucose becomes a simple yet powerful differentiator:

• Hypoglycemia suggests beta-blocker toxicity (impairs glycogenolysis).
• Hyperglycemia suggests calcium channel blocker (CCB) toxicity (impairs pancreatic insulin release).

Rescue Therapies for Cardiotoxicity

• Glucagon: I have used glucagon for years as a rescue in beta-blocker toxicity because its receptor pathway bypasses blocked beta receptors, increasing cAMP and cardiac contractility (Kerns, 2007). Dosing is typically 3–5 mg IV bolus, followed by an infusion, with premedication for nausea.
• High-Dose Insulin Euglycemia Therapy (HIET): For both CCB and beta-blocker toxicity, high-dose insulin is a robust therapy. It increases myocardial glucose uptake and enhances contractility. The protocol involves a 1 unit/kg IV bolus followed by an infusion, with co-infusion of dextrose (D10) and close monitoring of glucose and potassium to prevent hypoglycemia and hypokalemia (St-Onge et al., 2017).
• Intralipid Therapy: For lipophilic agents, intravenous lipid emulsions can create a “lipid sink” to sequester the toxin away from myocardial tissue and provide an energy substrate (Weinberg, 2010).

Toxic Alcohols, Inhalants, and Heavy Metals

Refractory Seizures, Anion Gap Acidosis, and Toxic Alcohols

A patient with refractory seizures and anion gap metabolic acidosis (Na − (Cl + HCO3) > 16) triggers a high-priority evaluation for toxic alcohols. An osmol gap > 10–15 further suggests a toxic alcohol.

• Ethylene glycol (antifreeze) is metabolized by alcohol dehydrogenase (ADH) to glycolic acid (causing acidosis) and oxalic acid. The oxalic acid binds with calcium to form calcium oxalate crystals, which precipitate in renal tubules, causing acute renal failure (Brent, 2009).
• Methanol (windshield washer fluid) is metabolized by ADH to formic acid, causing severe acidosis and optic nerve toxicity leading to blindness.
• Isopropanol (rubbing alcohol) metabolizes to acetone; it produces intoxication but not an anion gap acidosis.

Management Strategy:

The key is to block ADH.

1. Antidote Therapy (ADH Blockade):

• • Fomepizole (Antizol): This is the modern antidote of choice. It is a potent competitive inhibitor of ADH.
  • Ethanol (Historical): Before fomepizole, intravenous ethanol was used as a competitive substrate for ADH.

• Hemodialysis: Dialysis is often required to remove the parent alcohol and its toxic metabolites and to correct severe metabolic acidosis.
• Cofactor Administration: Thiamine and pyridoxine are adjunctive therapies.

Cyanide Poisoning: The Cellular Suffocator

Cyanide is a potent chemical asphyxiant, often inhaled in structural fires from burning plastics, wool, and silk. It prevents cells from using oxygen by inhibiting cytochrome c oxidase in the mitochondrial electron transport chain. This halts aerobic respiration, forcing cells into anaerobic metabolism, which generates a profound lactic acidosis. The classic “cherry-red” skin is a post-mortem finding. In a fire victim with altered mental status and severe tachypnea (Kussmaul’s respirations), I assume cyanide poisoning and initiate treatment immediately.

Modern Treatment: The Role of Hydroxocobalamin

The standard of care is hydroxocobalamin. This precursor to vitamin B12 has a cobalt ion that avidly binds cyanide, forming cyanocobalamin (vitamin B12), which is safely excreted in the urine. A dramatic but harmless side effect is that the patient’s urine will turn a deep, vibrant red.

Carbon Monoxide: The Silent Killer

Carbon monoxide (CO) is a colorless, odorless gas from incomplete combustion (furnaces, generators, car exhaust). It is dangerous because it has an affinity for hemoglobin that is 200-250 times greater than that of oxygen.

• It forms stable carboxyhemoglobin (COHb), reducing the blood’s oxygen-carrying capacity.
• It causes a leftward shift of the oxyhemoglobin dissociation curve, meaning the hemoglobin that is still carrying oxygen doesn’t release it effectively to the tissues.

The Pulse Oximeter’s Deception

A standard pulse oximeter cannot distinguish between oxyhemoglobin and carboxyhemoglobin. A patient with severe CO poisoning can have a pulse oximetry reading of 99-100%, giving a false sense of security. Diagnosis requires a CO-oximeter to measure the COHb level.

Treatment:

The treatment for CO poisoning is oxygen.

• 100% High-Flow Oxygen: Administered via a non-rebreather mask, this reduces the half-life of CO from 4-5 hours to about 60-90 minutes.
• Hyperbaric Oxygen Therapy (HBOT): For severe cases (loss of consciousness, seizures, cardiac ischemia, high COHb level), HBOT reduces the CO half-life to 20-30 minutes and may reduce the risk of delayed neurological sequelae.

Other Key Toxicities and Reversals

• Sulfonylurea-Induced Hypoglycemia: Sulfonylureas (e.g., glyburide) can cause prolonged, refractory hypoglycemia. The treatment is octreotide, a somatostatin analog that suppresses pancreatic insulin release, plus a continuous dextrose infusion (Howell et al., 1993).
• Anticoagulant Reversal:

• • Heparin: Protamine sulfate.
  • Warfarin: Vitamin K plus four-factor prothrombin complex concentrate (PCC), which is superior to plasma (Sarode et al., 2013).
  • Dabigatran (Pradaxa): Idarucizumab (Praxbind).
  • Rivaroxaban (Xarelto) & Apixaban (Eliquis): Andexanet alfa (Andexxa). Four-factor PCC is a less expensive, off-label alternative (Cuker et al., 2019).

• Benzodiazepine Oversedation: Flumazenil is a receptor antagonist but must be used with extreme caution. In chronic benzodiazepine users, it can precipitate life-threatening withdrawal seizures (Hoffman & Goldfrank, 1995). Its use is safer in reversing procedural sedation or in a pediatric accidental ingestion.
• Heavy Metal and Iron Toxicity: For iron overdose, often from pediatric ingestion of supplements, the chelating agent is deferoxamine. It binds free iron, forming ferrioxamine, which is excreted in the urine (Chyka et al., 2000).
• Vasopressor Extravasation: Peripheral infusion of vasopressors (e.g., norepinephrine) can leak, causing intense vasoconstriction and tissue necrosis. The rescue is immediate infiltration of the area with phentolamine, an alpha-adrenergic antagonist, to reverse vasoconstriction and restore perfusion.

The Role of Integrative Care in Recovery

While acute management is the domain of emergency and critical care, the journey to full recovery often extends long after the toxin has been eliminated. This is where our integrative approach at Injury Medical Clinic, PA, becomes invaluable. A severe poisoning is a profound physiological insult that can leave a lasting impact.

• Musculoskeletal and Neurological Rehabilitation: Patients recovering from poisonings that cause prolonged immobility, muscle weakness, or seizures can experience deconditioning, spasms, and postural imbalances.

• • Chiropractic Adjustments: Gentle and specific chiropractic adjustments can help restore proper spinal mechanics, improve nervous system communication, and alleviate secondary nerve impingement.
  • Soft Tissue and Rehabilitative Therapies: We utilize techniques like myofascial release and targeted exercises to address muscle tightness, reduce pain, and rebuild strength.

• Supporting Detoxification and Healing with Functional Medicine: The body’s detoxification systems have been under immense strain.

• • Liver and Gut Support: Following an event like acetaminophen toxicity, we use functional medicine principles to recommend nutrients (milk thistle, alpha-lipoic acid) to support Phase I and II detoxification pathways and protocols to restore a healthy gut microbiome.
  • Mitochondrial Health: Toxins like salicylates and CO directly poison mitochondria. We can use targeted nutrients like Coenzyme Q10, L-carnitine, and B vitamins to support mitochondrial function and combat persistent fatigue.

Under the watchful medical direction of Dr. Cardenas, these integrative therapies are safely woven into the patient’s overall recovery plan. This synergy between conventional medical oversight and integrative, hands-on care allows us to not only save a life in the acute phase but to restore quality of life in the long term. My ongoing clinical observations, shared across my professional platforms (dralexjimenez.com and LinkedIn), inform our protocols and guide refinements in breathing mechanics rehabilitation, HRV stabilization, and gradual return-to-function programs after acute toxicological events.

References

• Anseeuw, K., Delvau, N., Douglas, K., Ebo, D., Goffin, K., Lefevere, A., & Spriet, I. (2013). Hydroxocobalamin in cyanide poisoning: a systematic review. Clinical Toxicology, 51(7), 549–561.
• Barceloux, D. G., Krenzelok, E. P., Olson, K., & Watson, W. (1999). American Academy of Clinical Toxicology practice guidelines for the treatment of ethylene glycol poisoning. Journal of Toxicology: Clinical Toxicology, 37(5), 537-560.
• Bland, J. (2015). The Disease Delusion. HarperWave.
• Borron, S. W., & Baud, F. J. (2011). Antidotes for acute cyanide poisoning. Current Pharmaceutical Biotechnology, 12(9), 1903–1911.
• Boyer, E. W. (2012). Management of opioid analgesic overdose. New England Journal of Medicine, 367(2), 146–155.
• Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. The New England Journal of Medicine, 352(11), 1112–1120.
• Boyle, P. J., et al. (1993). Octreotide suppresses sulfonylurea-induced hypoglycemia. The Journal of Clinical Endocrinology & Metabolism, 76(2), 554–556.
• Brent, J. (2009). Fomepizole for ethylene glycol and methanol poisoning. New England Journal of Medicine, 360(21), 2216–2223.
• Bronstein, A. C., et al. (2011). 2010 Annual report of the American Association of Poison Control Centers’ National Poison Data System. Clinical Toxicology, 49(10), 910–941.
• Calder, P. C. (2020). Nutrition, immunity and COVID-19. BMJ Nutrition, Prevention & Health, 3(1), 74–92.
• Chun, L. J., Tong, M. J., Busuttil, R. W., & Hiatt, J. R. (2009). Acetaminophen hepatotoxicity and acute liver failure. Journal of Clinical Gastroenterology, 43(4), 342-349.
• Chyka, P. A., & Erdman, A. R. (1996). Evidence-based recommendations on the use of sodium bicarbonate in salicylate toxicity. Annals of Emergency Medicine, 27(2), 170–176.
• Chyka, P. A., et al. (2000). Deferoxamine for iron poisoning: A clinical review. Annals of Emergency Medicine, 36(3), 273–281.
• Connolly, S. J., et al. (2016). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. The New England Journal of Medicine, 375(12), 1131–1141.
• Cuker, A., et al. (2019). Reversal of DOACs: guidance from the American Society of Hematology. Blood Advances, 3(10), 1686–1699.
• Dart, R. C., & Rumack, B. H. (2012). Opioid analgesics. In Medical Toxicology (pp. 763–780).
• Dunkley, E. J. C., et al. (2003). The Hunter Serotonin Toxicity Criteria. QJM, 96(9), 635–642.
• Greene, S. L., et al. (2014). Beta-blocker and calcium channel blocker overdose: A review. Emergency Medicine Journal, 31(9), 743–748.
• Hampson, N. B., Piantadosi, C. A., Thom, S. R., & Weaver, L. K. (2012). Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. American Journal of Respiratory and Critical Care Medicine, 186(11), 1095–1101.
• Heard, K. (2008). Acetylcysteine for acetaminophen poisoning. The New England Journal of Medicine, 358(4), 431–442.
• Hoffman, R. S., & Goldfrank, L. R. (1995). The use of flumazenil in benzodiazepine overdose. Journal of Toxicology: Clinical Toxicology, 33(5), 515–517.
• Hoffman, R. S., et al. (1996). Toxidromes in the modern era: Clinical utility and limitations. Emergency Medicine Clinics of North America, 14(3), 615–635.
• Howell, J. M., et al. (1993). Octreotide for sulfonylurea-induced hypoglycemia. Annals of Emergency Medicine, 22(12), 1908–1911.
• Jones, D. S. (2012). Textbook of Functional Medicine. IFM Press.
• Juurlink, D. N. (2002). The medical management of salicylate poisoning. The American Journal of Emergency Medicine, 20(5), 394–401.
• Juurlink, D. N., Gosselin, S., Kielstein, J. T., Ghannoum, M., Lavergne, V., Nolin, T. D., & Hoffman, R. S. (2015). Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP workgroup. Annals of Emergency Medicine, 66(2), 165–181.
• Kariisa, M., et al. (2023). Xylazine detection and adverse events among illicitly manufactured fentanyl overdoses. MMWR, 72(12), 285–291.
• Kerns, W. (2007). Management of beta-blocker and calcium channel blocker toxicity. Emergency Medicine Clinics of North America, 25(2), 309–331.
• Kim, H. K., & Nelson, L. S. (2015). Naloxone for beta blocker and calcium channel blocker overdose: No direct effect, but supportive care persists. Clinical Toxicology, 53(5), 451–452.
• Kraut, J. A., & Madias, N. E. (2010). Metabolic acidosis: Pathophysiology, diagnosis and management. Nature Reviews Nephrology, 6(5), 274–285.
• Lacy, C. F., et al. (2020). Drug Information Handbook (29th ed.). Lexicomp.
• Lavonas, E. J., et al. (2015). Evidence-based guidelines for the out-of-hospital management of salicylate poisoning. Clinical Toxicology, 53(2), 95–110.
• Lawson-Smith, P., Tvedt, B., Hultén, P., & Anderson, H. (2011). Neuropsychological outcome after acute carbon monoxide poisoning in childhood. Pediatric Rehabilitation, 14(2), 119-127.
• Lee, W. M. (2017). Acetaminophen toxicity: Mechanisms, clinical manifestations, and management. Clinics in Liver Disease, 21(4), 559–574.
• Levine, M. (2006). Hemodialysis for salicylate poisoning. Journal of Medical Toxicology, 2(4), 165–166.
• Levine, M., & Ruha, A. M. (2012). Anticholinergic poisoning. Emergency Medicine Clinics of North America, 30(2), 329- 340.
• Nelson, L. S., Howland, M. A., Lewin, N. A., Smith, S. W., Goldfrank, L. R., & Hoffman, R. S. (Eds.). (2019). Goldfrank’s Toxicologic Emergencies (11th ed.). McGraw-Hill Education.
• Olson, K. R. (2007). Poisoning & Drug Overdose (5th ed.). McGraw-Hill.
• Olson, K. R. (2012). Poisoning & Drug Overdose (6th ed.). McGraw-Hill.
• O’Malley, G. F. (2007). Emergency department management of the salicylate-poisoned patient. Emergency Medicine Clinics of North America, 25(2), 333-346.
• Peter, J. V., Sudarsan, T. I., & Moran, J. L. (2014). Clinical features of organophosphate poisoning: A review of different classification systems and approaches. Indian Journal of Critical Care Medicine, 18(11), 735–745.
• Prescott, L. F. (1983). Paracetamol overdosage: Pharmacological considerations and clinical management. Drugs, 25(3), 290–314.
• Proudfoot, A. T. (1983). Toxicity of salicylates. The American Journal of Medicine, 75(5A), 99–103.
• Richards, J. R., Albertson, T. E., Derlet, R. W., Lange, R. A., & Horowitz, B. Z. (2015). Treatment of sympathomimetic-induced cardiovascular toxicity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35(6), 612-624.
• Rose, J. J., Wang, L., Xu, Q., McTiernan, C. F., Shiva, S., Tejero, J., & Gladwin, M. T. (2017). Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy. American Journal of Respiratory and Critical Care Medicine, 195(5), 596–606.
• Ruiz-Colón, K., et al. (2014). Xylazine intoxication in humans. Journal of Analytical Toxicology, 38(9), 605–610.
• Salhanick, S. D., & Shannon, M. W. (2007). Management of salicylate toxicity. Pediatric Emergency Care, 23(9), 640–643.
• Sarode, R., et al. (2013). Efficacy and safety of a four-factor prothrombin complex concentrate. Circulation, 128(11), 1234–1243.
• Siegal, D. M., et al. (2015). Idarucizumab for dabigatran reversal. The New England Journal of Medicine, 373(6), 511–520.
• Smilkstein, M. J., et al. (1988). Acetaminophen overdose: A prospective study of the effect of N-acetylcysteine. Journal of Pediatrics, 113(4), 693–698.
• Sobel, J. (2005). Botulism. Clinical Infectious Diseases, 41(8), 1167- 1173.
• St-Onge, M., et al. (2017). Expert consensus recommendations for the management of calcium channel blocker poisoning. Clinical Toxicology, 55(6), 471–484.
• Tardy, B., et al. (2013). Protamine sulfate in heparin reversal: A review. Journal of Thrombosis and Hemostasis, 11(8), 1461–1470.
• Temple, A. R. (2002). Acute and chronic effects of aspirin toxicity and their treatment. Archives of Internal Medicine, 162(11), 1117–1124.
• Tomaselli, G. F., et al. (2020). 2020 ACC Expert Consensus on management of bleeding in patients on oral anticoagulants. Journal of the American College of Cardiology, 76(5), 594–622.
• Weaver, L. K. (2009). Carbon monoxide poisoning. New England Journal of Medicine, 360(12), 1217–1225.
• Weinberg, G. L. (2010). Lipid rescue resuscitation for local anesthetic toxicity: Proof of clinical efficacy. Anesthesiology, 113(5), 1081–1083.
• Wermeling, D. P. (2015). Review of naloxone safety for opioid emergency use. Expert Opinion on Drug Safety, 14(5), 753–764.

SEO Tags: toxicology, integrative care, chiropractic, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, toxic emergencies, anticholinergic toxidrome, cholinergic crisis, sympathomimetic, activated charcoal, acetaminophen toxicity, N-acetylcysteine, ethylene glycol poisoning, fomepizole, salicylate poisoning, sodium bicarbonate, botulism, TCA overdose, organophosphate poisoning, atropine, 2-PAM, cocaine toxicity, carbon monoxide poisoning, cyanide poisoning, beta-blocker overdose, calcium channel blocker overdose, high-dose insulin therapy, intralipid, clonidine toxicity, xylazine, serotonin syndrome, anticoagulant reversal, PCC, idarucizumab, andexanet alfa, phentolamine extravasation, poison control, personal injury, rehabilitation